WednesdayJun 23, 2021 2:51 pm

Brain Scientific Inc. (BRSF) to Remain at the Forefront of Innovative Brain Diagnostics as the Sector Grows Across New Applications

As a leading innovator in brain diagnostics technology, BRSF appears well placed to spot and predict driving forces behind the industry's expected rapid growth  BRSF's Marketing Director was featured in an article giving prediction about key trends driving brain monitoring space in 2021 BRSF poised to remain at EEG forefront as exciting new opportunities lay ahead for this growing sector Recognized as a leading innovative player in the brain monitoring space, Brain Scientific (OTCQB: BRSF) continues to be at the forefront of what is next in neurology technology. The Company's Marketing Director, Irina Nazarova, was featured in Tech Times, a…

Continue Reading

TuesdayJun 22, 2021 3:00 pm

Customized Brain Maps Help Boost Cancer, Epilepsy Treatments Outcomes

A team of medical device developers, neuroscientists, surgeons and engineers from the University of California San Diego is working on developing better customized maps that will be useful to physicians during brain tumor removal surgery. Maps do already exist that physicians can reference. However, one individual’s brain isn’t the same as another’s, which is why customized maps are needed. Additionally, an individual’s brain may sometimes reorganize itself as a response to damage caused by things such as growing tumors, which can make it even harder to remove the tumor. This is where sensors enter the picture. Surgical teams can utilize…

Continue Reading

TuesdayJun 22, 2021 11:23 am

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer

Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes.  Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process. Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support system with right media for right ovarian cancer cell types Getting a drug through the complete FDA process, from pre-clinical to approval, is an arduous and expensive task, although there are signs that approval rates are accelerating after years of decline. Companion diagnostics, new approaches…

Continue Reading

MondayJun 21, 2021 2:05 pm

Analysis Uncovers Kidney Cancer Development, Response to Treatment

Researchers from the Rogel Cancer Center at the University of Michigan have sequenced the RNA of single cells in cancerous and benign kidney tumors. Using that information, they have  determined cells from which various subtypes originate and how the tumor micro-environment affects the development of cancer and an individual’s response to treatment. The researchers’ discoveries were reported in “Proceedings of the National Academy of Sciences” journal and will be useful in helping better understand what impacts renal cell carcinoma and in assisting oncologists in choosing the best treatment for each patient. This, in turn, will be beneficial to patients, given…

Continue Reading

MondayJun 21, 2021 12:10 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gains Inclusion on Russell 2000 Index as Brain Cancer Trial Enrollment Advances

Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition CNS’s focus has been on developing a means of combating glioblastoma, a fatal, generally incurable class of brain cancers that are aggressive and recurrent amid current surgical and chemotherapy interventions One patient from the Phase 1 trial of Berubicin 15 years ago remains cancer-free, as assessed in November, despite glioblastoma’s reputation for proving fatal generally within about 15 months of diagnosis CNS recently announced it will be included…

Continue Reading

MondayJun 21, 2021 11:41 am

Brain Scientific Inc. (BRSF) Pediatric-Specific Disposable EEG Cap Now Available

The company has developed and brought to market a pediatric NeuroCap  EEG testing in pediatrics may help diagnose autism, one of the fastest-growing developmental disorders in the US, and provide better treatment for pediatric patients with epilepsy  COVID-19 made the process challenging but the team completed their task on time despite no in-person contact and the process coming to a halt twice due to shutdowns Brain Scientific (OTCQB: BRSF), a health care company on a mission to modernize brain diagnostics with cutting-edge technologies, has developed and brought to market a pediatric-specific disposable EEG cap. The pediatric NeuroCap may aid in…

Continue Reading

FridayJun 18, 2021 2:36 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Making Advances in Bladder Cancer Treatment Through Proprietary Imaging Technology

Company’s i/Blue Imaging System(TM) is expected to be completed in 2022 The American Cancer Society estimates that 2021 will see 83,370 new cases of bladder cancer and approximately 17,200 deaths More than half of the patients who underwent a cystoscopy to remove non-muscle-invasive bladder cancer will experience recurrence  The bladder cancer market was valued at $3.43 billion in 2020, and is anticipated to reach $4.71 billion by 2028 According to the American Cancer Society, new cases of bladder cancer in the United States are expected to reach 83,730 in 2021 and deaths are anticipated to reach 17,200 (https://ibn.fm/zNRWl). Approximately 50%…

Continue Reading

FridayJun 18, 2021 2:24 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reports First Quarter Financials; Anticipates Improved Patient Outcomes with Berubicin

Company expects reporting on interim analysis for the first 18 patients of a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients during the first half of 2022 One patient from the first Berubicin trial has survived cancer-free for 14 years, while two patients saw tumor reduction of up to 80 percent CNS Pharmaceuticals reported a net loss of $3.6 million, attributed to increased personnel, activity preparing for clinical trials, drug manufacturing, and labor for the Phase 2 study The global brain tumor therapeutics market is expected to grow at a CAGR during 2020-2025, resulting in forecasted market…

Continue Reading

FridayJun 18, 2021 2:14 pm

How What You Eat Affects Your Brain Health

A recently released study discovered that individuals who routinely consumed processed meat along with sugary drinks and snacks that were high in sodium tended to have smaller left hippocampi, which is the part of the brain that is responsible for mental health, learning and memory. The study, which was conducted by researchers from the Australian National University and Deakin University, also found that older individuals who consumed healthier diets had larger hippocampi. The researchers concluded that a higher intake of unhealthy food and a lower intake of nutrient-dense foods were each independently linked to a smaller hippocampus volume, noting that…

Continue Reading

FridayJun 18, 2021 1:50 pm

RYAH Group Inc. (CSE: RYAH) Completes First Shipment of SMART Inhalers to UK Clinical Trial

The first shipment of SMART inhalers, 10,000 cartridges and QR codes arrived in the UK for the clinic's pilot run Due to the large scale of the clinical trial, RYAH developed a custom software solution for the clinic In the UK the medical cannabis market is expected to reach $1.3 billion by 2024, and 1% of the population could be medical cannabis patients by 2028 RYAH Group (CSE: RYAH), a connected device and big data and technology company, has completed its initial shipment to a major international clinic conducting a study in the UK on the safety and efficacy of…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050